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ABSTRACT
Human β-defensin-3 (hBD3) is an epithelial cell-derived innate immune 
regulatory molecule overexpressed in oral dysplastic lesions and fosters a tumor-
promoting microenvironment. Expression of hBD3 is induced by the epidermal growth 
factor receptor signaling pathway. Here we describe a novel pathway through which 
the high-risk human papillomavirus type-16 (HPV-16) oncoprotein E6 induces hBD3 
expression in mucosal keratinocytes. Ablation of E6 by siRNA induces the tumor 
suppressor p53 and diminishes hBD3 in HPV-16 positive CaSki cervical cancer cells 
and UM-SCC-104 head and neck cancer cells. Malignant cells in HPV-16-associated 
oropharyngeal cancer overexpress hBD3. HPV-16 E6 induces hBD3 mRNA expression, 
peptide production and gene promoter activity in mucosal keratinocytes. Reduction 
of cellular levels of p53 stimulates hBD3 expression, while activation of p53 by 
doxorubicin inhibits its expression in primary oral keratinocytes and CaSki cells, 
suggesting that p53 represses hBD3 expression. A p53 binding site in the hBD3 
gene promoter has been identified by using electrophoretic mobility shift assays 
and chromatin immunoprecipitation (ChIP). In addition, the p63 protein isoform 
ΔNp63α, but not TAp63, stimulated transactivation of the hBD3 gene and was co-
expressed with hBD3 in head and neck cancer specimens. Therefore, high-risk HPV E6 
oncoproteins may stimulate hBD3 expression in tumor cells to facilitate tumorigenesis 
of HPV-associated head and neck cancer.
INTRODUCTION
Human β-defensins (hBDs) are small cationic 
peptides originally identified from the plasma of patients 
with renal disease and from psoriatic skin lesions as 
innate antimicrobial molecules [1]. We have reported 
that proliferating oral mucosal basal layer cells as well as 
tumor cells in carcinoma in situ lesions and at the invasive 
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front of squamous cell carcinoma produce hBD3, which 
is encoded by the DEFB103A gene, with little-to-no 
expression of hBD-1 and -2 [2, 3]. However, differentiated 
epithelial cells of oral epithelia only express hBD-1 
and -2 [2, 3]. Tumor cell-derived hBD3 is associated 
with recruitment and activation of tumor-associated 
macrophages (TAMs) in the tumor microenvironment, 
thus contributing to tumor progression [2, 3]. We have 
reported that hBD3 expression is induced by activation 
of epidermal growth factor receptor (EGFR) [2]. The 
EGFR signaling pathway is also critical for hBD3 gene 
expression in cells following microbial insults [4]. 
Cetuximab (Erbitux), a humanized monoclonal antibody 
against EGFR, blocks LPS-induced hBD3 expression, 
indicating the importance of EGFR in modulation of 
hBD3 gene expression [4].
Human papillomaviruses (HPV) are non-lytic, non-
enveloped viruses containing a small (~ 8 kbp), double-
strand circular DNA genome encoding 6 early (E) and 
2 late (L) proteins [5]. HPV infection by high-risk HPV 
types, particularly HPV-16 and -18, predisposes women 
to cervical cancer and acts as independent predictors for 
increased risk for the development of anal, penile, and 
vulvar cancers [5, 6]. Recent studies have also revealed 
a causal link between chronic HPV infection and a subset 
of head and neck squamous cell carcinomas (HNSCC), 
particularly tumors that arise largely from the lingual and 
palatine tonsils in the oropharynx [7]. HPV-16 is the most 
commonly detected HPV DNA in HNSCC, accounting 
for up to 90-95% of all HPV-associated HNSCC [7-9]. 
High-risk HPV E6 protein has been demonstrated to 
complex with the cellular ubiquitin ligase E6AP and p53, 
resulting in ubiquitination and degradation of the tumor 
suppressor p53 [10]. E7 binds to all members of the 
retinoblastoma (RB) gene family, leading to release of the 
repressive function and up-regulation of proteins involved 
in cell cycle progression [10]. Collectively, the oncogenic 
capacity of E6 and E7 proteins allows for maintenance 
of proliferation and inappropriate centrosomal and 
chromosomal duplication; frequently leading to malignant 
transformation [10].
Although oncogenic E6 and/or E7 proteins lead to 
reduced production of monocyte chemoattractant protein-1 
(MCP-1) and other chemokines [11], TAMs still infiltrate 
HPV-16-associated tumors, resulting in suppression of 
an antitumor T cell response, thereby facilitating tumor 
growth [12]. Expression of human β-defensins and 
other antimicrobial peptides has been detected in HPV-
associated vulvovaginal lesions and anal intraepithelial 
neoplasia [13, 14]. However, the production of hBD3 in 
HPV-associated HNSCC and the role of HPV oncoproteins 
in modulating hBD3 expression are still unknown. In 
the current study, we report that (1) clinically confirmed 
HPV-positive head and neck cancers overexpress hBD3, 
(2) HPV-16 E6 induces hBD3 expression in human oral 
epithelial cells and oral cancer cell lines when compared to 
E6 from non-oncogenic HPV types, and (3) this induction 
appears to be inversely regulated by p53 and induced by 
ΔNp63α. Our study therefore supports hBD3 as a novel 
HPV regulated factor that facilitates HPV-associated 
tumor development and progression.
RESULTS
Expression of hBD3 in HPV-positive cancer cells
We tested specificity of commercially 
available HPV-16 E6 antibodies by performing 
immunofluorescence microscopy on HPV-positive CaSki 
cervical cancer cells, which contain multiple copies 
of integrated HPV-16 genome. The goat polyclonal 
antibody against HPV-16 E6 (N-17) (Santa Cruz 
Biotech Inc.) showed nuclear E6 staining in CaSki cells 
(Figure 1A), but not in that of HPV-negative TR146 
oral cancer cells (Supplementary Figure S1). Addition 
of the blocking peptide to the N-17 antibody eliminated 
E6 staining (Figure 1A). The goat IgG isotype control 
antibody did not show this fluorescence signal in CaSki 
cells (Supplementary Figure S1). In addition, a mouse 
monoclonal antibody to HPV-16/18 E6 (C1P5, Santa 
Cruz Biotech Inc.) only showed cytoplasmic staining 
(Supplementary Figure S1). It has been shown that 
reduction of HPV gene expression by HPV-16 E6 siRNA 
is associated with increase in the level of nuclear p53 
in CaSki cells [15]. To further validate the goat anti-
HPV-16 E6 antibody, CaSki cells were transfected with 
an HPV-16 E6 siRNA or a control siRNA, followed by 
immunofluorescence microscopy for HPV-16 E6 and 
p53. The polyclonal HPV-16 E6 antibody did not detect 
the E6 protein in CaSki cells transfected with the E6 
siRNA, while the monoclonal antibody to p53 identified 
nuclear p53 protein in the cells (Figure 1B). In addition, 
control siRNA had no effect on nuclear staining of E6 
with undetectable p53 in CaSki cells (Figure 1B). To 
determine hBD3 expression in HPV-positive cancer 
cells, we performed immunofluorescent double-staining 
on CaSki cells using a polyclonal antibody to hBD3 and 
the antibody against E6. CaSki cells expressed hBD3 
in the cytoplasm with co-expression of nuclear E6 in 
cells transfected with the control siRNA (Figure 1C, left 
panel). However, transfection of CaSki cells with the E6 
siRNA blocked hBD3 as well as nuclear E6 expression 
(Figure 1C, right panel). These results suggest association 
of hBD3 expression with E6 in HPV-positive cancer cells.
Expression of hBD3 in HPV-positive head and 
neck (HNC) cancer
High-risk HPV infection is a causal factor for a 
subset of head and neck cancer, particularly those arising 
from the lingual and palatine tonsils in the oropharynx [7]. 
We have demonstrated that hBD3 overexpression in head 
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Figure 1: Association of hBD3 expression with HPV-16 E6 in CaSki cells. A. CaSki cells were stained with the goat polyclonal 
antibody to HPV-16 E6 (upper panels, - blocking peptide) or the antibody pre-incubated with the blocking peptide (+ blocking peptide). 
E6, green; nuclei, blue (DAPI). 20x. B. CaSki cells were transfected with the E6 (left panel) or a control siRNA (right panels), followed by 
immunofluorescent staining of HPV-16 E6 (red) and p53 (green). Nuclei, blue (DAPI). 20x. C. CaSki cells were transfected with a control 
or the E6 siRNA and then stained for hBD3 (red) and HPV-16 E6 (green). Nuclei, blue (DAPI). 20x.
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and neck neoplastic cells is associated with accumulation 
and activation of tumor-associated macrophages and may 
facilitate cancer progression [3]. To determine if HPV-
associated head and neck cancer produce hBD3 and the 
role of HPV oncoproteins in modulating hBD3 expression, 
HPV-16-positive UM-SCC-104 head and neck cancer 
cells [16] were transfected with HPV-16 E6 or a control 
siRNA, followed by immunofluorescence microscopy for 
hBD3 and E6. Control siRNA transfected cells showed 
cytoplasmic hBD3 and nuclear E6 expression (Figure 
2A, left panel). The blocking peptide of the HPV-16 E6 
antibody eliminated E6 staining, but not hBD3, in UM-
SCC-104 cells (Figure 2A, right panel). Transfection of 
cells with the E6 siRNA blocked expression of both E6 
and hBD3 (Figure 2B, left panel), but induced that of p53, 
in UM-104-SCC cells (Figure 2B, right panel), suggesting 
the association of hBD3 expression with HPV-16 E6 in 
HPV-positive HNSCC cells. To evaluate the expression 
of hBD3 in HPV-associated HNSCC specimens, we 
first genotyped high-risk HPVs using a multiplex PCR 
approach by amplifying E6 and E7 for each of 13 high-
risk HPV types, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 68, on genomic DNA extracted from 4 HNC 
specimens. Two oropharyngeal cancer samples were found 
to be HPV-16 E6 positive with a specific 223 bp band, 
while two oral squamous cell carcinoma (OSCC) samples 
were HPV-16 E6 negative (Figure 2C). We did not detect 
any other high-risk HPVs in these oropharyngeal cancer 
specimens. To ensure the quality of the genomic DNA, 
a 133 bp region of the β-actin gene in all genomic DNA 
samples was amplified with predicted size in all samples 
(Figure 2C). We then determined whether HPV-16 E6 and 
hBD3 could be detected in biopsy specimens by using 
immunofluorescence microscopy. Immunofluorescence 
images show high levels of hBD3 in the cytoplasm of 
cancer cells co-expressing HPV-16 E6 protein in their 
Figure 2: Expression of hBD3 in HPV-16 positive oropharyngeal cancer specimens. A. UM-SCC-104 cells grown in cell 
culture glass slides were transfected with control siRNA and then stained with the goat polyclonal antibody to HPV-16 E6 in the absence 
(right panels, - blocking peptide) or presence of the blocking peptide (right panels, +blocking peptide). hBD3, red; E6, green; nuclei, blue 
(DAPI). 20x. B. UM-SCC-104 cells were transfected with the E6 siRNA, followed by immunofluorescent staining of hBD3 (red) and 
HPV-16 E6 (green, left panel) as well as p53 (red) and HPV-16 E6 (green, right panel). Nuclei, blue. 20x. C. Multiplex high-risk HPV 
genotyping on head and neck cancer genome DNA. 1, 2, oropharyngeal cancer biopsies; 3, 4, oral squamous cell carcinoma biopsies; +, a 
positive control DNA derived from a cervical cancer patient specimen with confirmed HPV-16; M, DNA molecular weight markers. Only 
HPV-16 (arrow head) genotyping and β-actin genomic DNA (arrow) gel images are shown. D. Immunofluorescence microscopy of hBD3 
(red, arrowheads in enlarged inset) and HPV-16 E6 (green, arrows in enlarged inset). H&E; H&E stain from the same specimen. 20x.
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nuclei (Figure 2D). This phenotype of co-localization 
of cytoplasmic hBD3 and nuclear HPV-16 E6 suggests 
that cancer cells of HPV-associated HNSCC overexpress 
hBD3.
Induction of hBD3 gene expression by HPV-16 
E6
To determine whether HPV-16 E6 directly regulates 
hBD3 expression, immortalized OKF6/TERT-2 human 
oral keratinocytes were transiently transfected with the 
HPV-16 E6 expression construct, followed by RT-PCR 
of hBD3 mRNA. The expression of hBD3 mRNA was 
induced by HPV-16 E6 in OKF6/TERT-2 cells comparably 
to those treated with PMA, a known inducer of hBD3 [2] 
(Figure 3A). Transfection of primary human oral epithelial 
cells (HOECs) [2] with the HPV-16 E6 expression 
construct also induced hBD3 mRNA by over 30-fold as 
measured by real-time quantitative RT-PCR (qRT-PCR) 
(Figure 3B). In addition, HPV-16 E6 induced production 
of hBD3 peptide in HOECs and two HPV-negative oral 
cancer cell lines SasL1 and TR146 as determined by hBD3 
ELISA using cell lysates (Figure 3C). HPV E6 expression 
undergoes alternative splicing to generate various 
transcripts that have been identified in cervical cancer 
cell lines and HPV-16 immortalized keratinocytes [17]. 
Transcription from the early viral promoter p97 generates 
E6, E6f*1, and E6*2 mRNA species that can be detected 
by RT-PCR in several cervical cancer cell lines [17]. To 
determine whether these spliced forms were expressed 
in transient transfection of the HPV-16 E6 expression 
construct, we performed RT-PCR on total RNA isolated 
from HOECs transfected with the HPV-16 E6 expression 
vector using primers that covered the full length of the 
E6 transcript. The RT-PCR only resulted in a single band 
that represented un-spliced mRNA species of HPV-16 E6 
(Figure 3D), indicating that transient transfection of the 
HPV-16 E6 gene does not generate alternative splicing 
transcripts and that un-spliced E6 is responsible for 
inducing hBD3.
Figure 3: Induction of hBD3 expression by HPV-16 E6. A. RT-PCR for hBD3 and human β-actin mRNA on total RNA extracted 
from OKFT6/TERT-2 cells that were transfected with the HPV16 E6 expression construct. PMA, phorbol 12-myristate-13-acetate (PMA) 
treated cells, positive controls; Ctrl, mock transfection control. B. Fold induction of hBD3 mRNA in HOECs transfected with the HPV-16 
E6 expression construct. Cells transfected with the pcDNA3 vector (pcDNA3) and mock transfection (Ctrl) were used as negative controls. 
*, p≤ 0.05 (n=3). C. HOECs and SasL1 and TR146 oral cancer cells were transfected with the HPV-16 E6 expression construct for 48 hr, 
followed by hBD3 ELISA of cell lysates. Production of hBD3 peptide was presented as fold-increase of hBD3 produced by cells transfected 
with the HPV-16 E6 expression construct compared with those transfected with pcDNA3. *, p≤ 0.05 (n=3). D. RT-PCR of total RNA 
derived from HEK293 cells transfected with HPV-16 E6, or a pcDNA3 vector. Ctrl, mock transfected cells.
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Transcriptional regulation of hBD3 gene 
expression by HPV-16 E6 and the effect of low- 
and high-risk E6 on hBD3 expression
To identify the HPV-16 responsive elements in 
the hBD3 gene promoter, HOECs were transfected with 
a reporter construct that contains a ~1.5 kbp promoter 
region of the hBD3 gene driving the expression of firefly 
luciferase, together with the HPV-16 E6 expression 
construct for measurements of the reporter luciferase 
activity. HPV-16 E6 promoted luciferase activity 
significantly higher than the blank pcDNA3 vector 
(Figure 4A), indicating that E6 induces expression of 
hBD3 at the transcriptional level. HEK293 cells have been 
Figure 4: High-risk, but not low-risk, HPV E6 induces expression of hBD3. A. Luciferase analysis in HOECs transfected 
with HPV-16 E6 expression construct or a blank pcDNA3 vector together with the hBD3 luciferase reporter. Relative luciferase units 
represent hBD3 promoter activity after normalized with the Renilla luciferase activity using the dual-luciferase system. *, p≤ 0.05 (n=3). 
B. Luciferase analysis in HEK293 cells transfected with HPV-16 E6, or an MEKK expression construct together with the hBD3 luciferase 
reporter. *, p≤ 0.05 (n=3). C. Western blotting on p53 protein in HEK293 cells transfected with E6 expression construct of HPV-16 or -11. 
D. Real-time qRT-PCR of HOECs transfected with E6 expression construct of HPV-16 or -11. *, p≤ 0.05 (n=3). E. Real-time qRT-PCR of 
E6 mRNA of HPV-16 and -11 in HOECs transfected with respective expression constructs. Transfection with the blank pcDNA3 vector 
was used as a negative control. *, p≥ 0.56. F. hBD3 gene promoter reporter analysis in HOECs transfected with E6 expression construct 
of HPV-16, -11, or -32. *, p≤ 0.05 (n=3). Luciferase fold-induction indicates relative luciferase units of cells transfected with expression 
constructs compared to that transfected with the blank pcDNA3 vector (Ctrl).
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used for investigating interactions of ectopic proteins with 
p53, since the cell line contains wild-type p53 and serves 
as a transfection host for exogenous gene expression 
[15, 18]. Transfection of the HPV-16 E6 expression 
vector produced E6 in HEK293 cells by western blotting 
(Supplementary Figure S2). As in HOECs, HPV-16 
E6 significantly induced activation of the hBD3 gene 
promoter, comparable to that caused by the MEKK1 
expression construct [2], in HEK293 cells (Figure 4B).
High-risk HPV E6 proteins induce degradation 
of the tumor suppressor p53 protein through the E3 
ubiquitin ligase activity of E6AP and, together with the 
E7 oncoprotein, promotes carcinogenesis. However, low-
risk E6 proteins, such as those found in HPV-11, do not 
degrade p53 [19]. Therefore, we questioned whether E6 
proteins of high- and low-risk HPVs would differentially 
modulate hBD3 expression. HPV-16 E6, but not that of 
HPV-11 E6, diminished p53 in HEK293 cells (Figure 4C). 
HPV-16 E6 induced significantly higher levels of hBD3 
mRNA than HPV-11 E6 in HOECs (Figure 4D); while 
expression levels of these E6 genes were the same (Figure 
4E). Similarly, HPV-16 E6, but not HPV-11 or HPV-32 E6, 
another low-risk species, induced significant activation of 
the hBD3 gene promoter in HEK293 cells (Figure 4F). 
These results suggested that reduction of the p53 protein 
was associated with the induction of hBD3 expression.
Modulation of hBD3 expression by the tumor 
suppressor protein p53
We proposed that p53 would repress hBD3 gene 
expression. Indeed, HOECs produced hBD3 without 
visible p53 protein in response to EGF treatment as 
shown by immunofluorescence microscopy analysis 
(Figure 5A). Treatment of HOECs with Doxorubicin 
(DXR), an anthracycline antibiotic that up-regulates 
Figure 5: Effect of p53 on hBD3 expression. A. HOEC cells were treated with EGF (10 ng/ml) or doxorubicin (DXR, 1.25 µM) for 
16 hr, followed by immunofluorescent staining with antibodies to hBD3 (green) and p53 (red). Nuclei, blue (DAPI). 20x. B. Effect of the 
p53 inhibitor pifithrin-α on hBD3 and BIRC5 (survivin) expression in HOECs using RT-PCR. C. Effect of pifithrin-α (PIF) and DXR on 
the promoter activity of the hBD3 gene in HOECs. D. Effect of p53 inhibitor (pifithrin-α), activator (nutlin-3) and siRNA targeting p53 on 
transactivation of the hBD3 gene promoter in HEK293 cells. The assay was conducted in triplicates and repeated three times. *, p≤ 0.05 
(n=3). E. Western blotting of acetylated p53 (Ac-p53), total p53, and GAPDH in CaSki cells treated with EGF (20 ng/ml), PMA (5 nM), 
and DXR at different concentrations for 16 hr. F. qRT-PCR of hBD3 mRNA in CaSki cells treated with DXR (2.5 µM), EGF (20 ng/ml), 
and PMA (5 nM) for 16 hr. Ctrl, no treatment. *, p≤ 0.05. The experiment was repeated 3 times.
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and activates p53 [20], induced expression and nuclear 
translocation of p53, concomitantly inhibiting production 
of hBD3 (Figure 5A). In addition, inactivation of p53 
by pifithrin-α, a small molecular agent that inhibits 
transcriptional activity of p53 [21], induced mRNA 
expression of hBD3 and BIRC5 (Survivin), a protein 
known to be repressed by p53 [22] (Figure 5B). While 
pifithrin-α stimulated the activity of the hBD3 gene 
promoter, DXR blocked it in HOECs (Figure 5C). 
Pifithrin-α and p53 siRNA also enhanced hBD3 promoter 
activity in HEK293 cells (Figure 5D). However, treating 
cells with nutlin-3, which enhances accumulation of p53 
by antagonizing the p53 modulatory protein MDM2 
[23], did not induce promoter activity (Figure 5D). 
Acetylation plays a positive role in the accumulation and 
transcriptional activation of p53 protein in stress response 
[24]. HPV-positive CaSki cervical cancer cells contain 
wild-type p53, which can be acetylated in response to 
DXR treatment [25]. To determine the expression profile 
of hBD3 and its association with p53 in CaSki cells, we 
treated the cells with DXR, EGF, and PMA. DXR induced 
acetylation of p53, while EGF and PMA had no effect on 
its protein levels and acetylation (Figure 5E). Accordingly, 
hBD3 expression was significantly reduced in CaSki cells 
treated with DXR compared with those treated with EGF, 
PMA, or remained un-treated (Ctrl) (Figure 5F). Our 
results suggest that p53 functions as a transcriptional 
repressor of hBD3 gene expression and that HPV-16 
E6 can modulate hBD3 expression in a p53-dependent 
mechanism.
Binding of p53 to the hBD3 gene promoter 
and induction of hBD3 gene transactivation by 
ΔNp63
p53 functions as a transcription factor by directly 
binding to promoter sequences or via indirect protein-
protein interaction. Our data showed that p53 repressed 
hBD3 expression at the transcriptional level; we therefore 
postulated that p53 directly bound to p53 response 
element(s) of the hBD3 gene promoter, resulting in 
inhibition of the hBD3 promoter activity. To identify 
putative p53 binding sites in the hBD3 promoter, the 
1.5 kbp hBD3 gene promoter region was analyzed by 
PROMO, a virtual laboratory for the prediction of putative 
transcription factor binding sites in DNA sequences based 
on the TRANSFAC database [26]. Computational analysis 
identified several putative p53 binding sites. To determine 
p53 binding to the putative responsive elements within the 
DNA probe as identified by the program, electrophoretic 
mobility shift assays (EMSA) were performed using 
purified recombinant p53 protein with biotin-labeled 
oligonucleotide probes. One such putative binding 
sequence, starting at -1339 upstream of the transcription 
start site (Figure 6A), bound to purified recombinant p53 
protein (Figure 6B). Binding was abolished by addition 
of excess amount of un-labeled oligonucleotides (Figure 
6B). To further confirm that the probe contained p53 
responsive elements, we generated a mutant probe with 
three nucleotide mutations (Figure 6A) for EMSA. The 
mutant probe failed to bind to the recombinant p53 
protein to induce the shifted band (Figure 6B), indicating 
that the p53 responsive element contains sequences 5’- 
CTGTCTGCCC and 5’-CCCTACATTGG in the hBD3 
gene promoter. To determine the presence of p53 in the 
hBD3 promoter in vivo, chromatin immunoprecipitation 
(ChIP) assays were conducted using OKF6/TERT2 cells, 
which were treated with 1.25 µm of DXR for 5 hr to induce 
p53 (Figure 6C), followed by crosslinking of protein-
chromatin complexes by formalin and precipitation of the 
complexes using the monoclonal antibody to human p53. 
ChIP data showed that DXR induced enrichment of the 
p53-chromatin complexes by about 225-fold at the p53 
binding site located at -1339 bp, compared to cells without 
DXR treatment, indicating that p53 physically binds to the 
hBD3 promoter in vivo (Figure 6D). In the ChIP assay, the 
binding of p53 to the p53 responsive element of the p21 
gene was also identified and served as a positive control 
(Figure 6D).
As shown in Figure 3C, the E6 protein induced 
hBD3 expression in HOECs and the SasL1 HNSCC 
cell line containing a wild-type p53 [27, 28]. However, 
E6 protein also stimulated hBD3 expression in TR146 
HNSCC cells that have a disruptive p53 gene [29, 30], 
suggesting that E6 can modulate hBD3 gene expression 
in a p53-indipendent fashion. The p53 paralogue, p63 
protein, has been shown to partially overlap promoter-
binding activity with p53 [31]. p63 is encoded by the 
TP63 gene to produce the full-length TAp63, which 
contains the N-terminal transactivation (TA) domains, 
and the ΔNp63 isoforms, which lack TA domains and 
are deficient in transactivation [31]. p63 participates in 
modulating expression of several p53 repressive genes, 
including CD44 and BIRC5 [32, 33]. To evaluate the 
effect of p63 on regulation of hBD3 expression, HOECs 
were grown in keratinocyte culture medium supplemented 
with EGF treated with DXR or with DXR plus excess 
amount of EGF, followed by western blotting of total p63, 
p53, and hBD3 proteins. We found that p63 and hBD3 
proteins in HOECs grown in control culture medium 
were significantly higher compared to those in cells 
treated with DXR with or without excess amount of EGF 
(Figure 7A). However, DXR significantly induced p53 
protein in HOECs (Figure 7A). The expression pattern 
of p63 and hBD3 proteins vs. that of p53 in HOECs 
were quantified (Figure 7B). Since the antibody to p63 
in the western blotting recognizes all isoforms of p63, 
we decided to evaluate whether TAp63 or ΔNp63α was 
involved in modulation of hBD3 gene expression using 
promoter reporter assays of the hBD3 gene. We found that 
ΔNp63α, but not TAp63, induced activity of the hBD3 
gene promoter (Figure 7C). To assess the association 
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of hBD3 and p63 in patient samples, HNSCC biopsy 
specimens were stained for hBD3 and p63 and showed 
concomitant expression of hBD3 and p63 in cancer cells 
(Figure 7D). Our results indicate that ΔNp63α, in contrast 
to p53, induces hBD3 expression and that HPV-16 E6 may 
modulate hBD3 gene expression in a p53-independent 
mechanism, probably via activation of p63.
DISCUSSION
Recent epidemiological and molecular studies have 
determined that HPV-associated head and neck cancers 
are on the rise [7, 34-36]. TAMs have been shown to 
significantly enhance the development and progression 
of HPV-related cancers by releasing tumor-promoting 
cytokines, chemokines, and growth factors into the tumor 
microenvironment [12, 37, 38]. Migration of macrophages 
to the anatomical sites of tumors has been described to be 
mediated by MCP-1/CCL2 in a variety of cancers [39]. 
However, MCP-1 expressing tumor cells in head and 
neck cancer are rare and not correlated with macrophage 
migration in biopsy samples of these cancers [2]. We 
reported that oral carcinoma in situ lesions overexpress 
hBD3 with little-to-no expression of MCP-1 [2, 3] and that 
tumor cell-derived hBD3 is associated with accumulation 
of TAMs in the lesion site [3]. Furthermore, hBD3 
induces migration of human and mouse monocytes via the 
chemokine receptor CCR2 [3], suggesting that hBD3 may 
contribute to the recruitment of TAMs [3]. In the present 
study, we first rigorously validated a polyclonal antibody 
using HPV-16 positive CaSki cervical cancer cells and 
then demonstrated that high-risk HPV E6 was co-localized 
Figure 6: Identification of p53 binding site in the hBD3 gene promoter. A. Putative p53-binding site in the hBD3 promoter 
identified by computational analysis. The p53 responsive element was underlined. Mutant oligonucleotides in the p53 responsive sequence 
are marked as bold/italicized letters. B. EMSA of recombinant p53 protein with hBD3 promoter derived, biotin-labeled oligonucleotides 
(probe) as shown in A. Shifted band is indicated by an arrow. Un-labeled oligonucleotides were used as competitors to ensure the specificity 
of the binding. Mutated probe (mut probe) failed to induce shifted p53/probe complex. C. OKF6/TERT-2 cells were treated with doxorubicin 
followed by immunofluorescent staining for p53 (red). Nuclei, blue (DAPI). 20x. D. ChIP analysis of p53 interaction with the hBD-3 
promoter in vivo. OKF6/TERT-2 cells treated with or without DXR (+/- DXR) were used in ChIP assays using qPCR. The abundance of p53 
binding sites was represented as the ratio of DNA derived from p53 antibody precipitation (anti-p53) vs. that from control IgG incubation 
(IgG). -1339, the putative p53 binding site in the hBD3 gene promoter; -179, the site of a genomic DNA fragment without p53 binding; 
p21, ChIP on the p53 binding site in the p21 gene. The experiment was repeated two times.
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with hBD3 in HPV-positive head and neck cancer tissues. 
In addition, transfection of cultured epithelial cells with 
the HPV-16 E6 expression vector induced hBD3 mRNA 
expression, suggesting that HPV-16 E6 may be the causal 
agent for hBD3 expression in HPV-positive head and neck 
cancer. Interestingly, E6 proteins of low-risk HPVs were 
not able to induce transactivation of the hBD3 promoter 
compared to that of HPV-16. Therefore, hBD3 induced 
by E6 of high-risk HPVs may facilitate accumulation 
and activation of TAMs in the tumor microenvironment, 
resulting in suppression of the acquired immune response 
to tumor cells, and thereby promote carcinogenesis in the 
head and neck region.
We have reported that EGF induces the expression 
of hBD3 in oral epithelial cells via MAP kinases p38 
and JNK, PI3K/AKT, and PKC [2]. In addition, hBD3 is 
expressed in proliferating cell nuclear antigen (PCNA)-
positive basal cells in normal oral mucosa and in tumor 
cells of oral carcinoma in situ lesions [2]. Herein, we 
focused on how expression of hBD3 was modulated by 
HPV-16 E6 protein. HPV-16 is responsible for the majority 
(~ 90% to 95%) of HPV-positive oropharyngeal squamous 
cell carcinomas [9], in which predominantly wild-type 
p53 is inactivated by E6. This inactivation occurs through 
two distinct mechanisms: (1) E6 protein associates with 
the cellular E6 association protein (E6AP, UBA3), an E3 
ubiquitin ligase, to recruit p53 for degradation via the 
proteasome pathway, and (2) it also interacts with p300 
and Ada3 to block p300-mediated p53 acetylation, an 
essential protein modification for p53 activation [40-42]. 
Our results showed that inactivation of p53 significantly 
induced hBD3 expression. However, activation of p53 
suppressed hBD3 expression. These data indicate that p53 
suppresses hBD3 gene expression.
Identification of a p53-regulated gene requires that 
three criteria be met; these include: (1) the presence of a 
p53 responsive element in the DNA close to or within the 
gene, (2) up- or down-regulation at the mRNA and protein 
levels as well as the gene promoter responses to p53, and 
(3) identification of p53 binding sequences in the gene 
promoter region by either ChIP assays or EMSA [43]. 
Recent studies indicate that a majority of p53-repressed 
Figure 7: Role of p63 in modulation of hBD3 expression. A. HOECs were grown in basal medium with supplements, following 
addition of EGF (10 ng/ml) and DXR (1 µM) for 20 hr. Western blotting for p53, p63, and hBD3 was performed with GAPDH as a 
housekeeping control. B. Quantification of western blotting densities in A. C. Luciferase activities in HEK293 cells co-transfected with 
the hBD3 gene promoter reporter and expression constructs as indicated. RLU, relative luciferase units. pcDNA blank vector transfection 
was used as a negative control. Luciferase activities were determined using the Dual-luciferase system. *, p<0.05. D. Expression of hBD3 
and p63 in HNSCC specimens using immunofluorescence microscopy. A representative image is shown. Arrows, p63 (red); arrow heads, 
hBD3 (green); nuclei, blue (DAPI). 20x.
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genes are regulated by binding of p53 at the distal region of 
the genome to interfere with the activity of the enhancers 
of p53-repressed genes [44]. For example, in the absence 
of p53, transcription enhancers at the distal region of 
Nanog, one of the p53-repressed core transcription factors 
critical for pluripotency in mouse embryonic stem cells, 
contribute to activation of Nanog transcription. However, 
binding of p53 at the enhancers inhibits enhancer activity, 
resulting in repression of Nanog expression [44]. In this 
report, we have identified a potential p53 binding site 
at -1339 upstream of the transcription start site in the 
hBD3 promoter via EMSA and ChIP analysis. The fact 
that the p53 binding site is located in the hBD3 promoter 
suggests that p53 can repress hBD3 expression by directly 
binding to the p53 responsive elements of the hBD3 gene 
promoter.
The canonical p53 binding sites in the genome 
generally consist of two copies of the degenerated 
sequences 5’-PuPuPuC(A/T)-3’ arranged head-to-head and 
divided by a spacer of 0-21 base pairs [43]. The half-sites 
vary in size between 8 to 12 bp, but most have 10 bp [43]. 
Our results show that the p53 binding site in the hBD3 
gene promoter contains two half-sites 5’-CTGTCGACCC 
and 5’-CCCTAAATTG separated in the head-to-tail 
arrangement, which has been reported in other p53-
repressed genes, such as ARF, CCNA, and CD44 [32, 45, 
46]. Therefore, our date indicate that suppression of hBD3 
expression by p53 uses the same mechanism.
p53 mutation is a frequent event in HPV-negative 
HNSCC [47, 48]. It has been shown that over 70% of 
HNSCC cases contain p53 mutations [49]. In this report, 
we have shown that transfection of HPV-16 E6 gene 
induced hBD3 protein expression in SasL1 and TR146 
HNSCC cell lines (Figure 3C). SasL1 is a subline of the 
SAS tongue carcinoma cell line that contains a p53 with 
wild-phenotype [27, 28, 50], while the TR146 cell line, 
which was derived from a cervical lymph node metastasis 
that originated from a well-differentiated buccal HNSCC 
[51], has a homozygous mutation in exon 7 of the TP53 
gene [29, 30]. Our results showed that HPV-16 E6 induced 
expression of hBD3 mRNA in both wild-type and mutant 
p53 HNSCC cell lines, suggesting that HPV-16 E6 can 
induce hBD3 gene expression in a p53-dependent and 
p53-independent pathways. Various isoforms of p63 are 
highly expressed in the basal layers of epithelia and play 
important roles in stem cell homeostasis [52]. TAp63 
can inhibit tumorigenesis and metastasis in vivo, while 
ΔNp63 isoforms, particularly ΔNp63α, is involved in 
tumorigenesis [53-55]. It has been shown that cervical 
squamous cell carcinomas over-produce p63 and that 
cervical carcinoma cell lines constitutively express 
ΔNp63α [56-58]. In addition, ΔNp63α is predominantly 
produced in undifferentiated normal human foreskin 
keratinocytes (NHKs) compared to differentiated NHKs. 
However, HPV E6 and E7 proteins cause retention 
of ΔNp63α expression in differentiated NHKs [59]. 
In addition, it has been shown that ΔNp63 and p53 
antagonize with each other during tissue development and 
tumorigenesis [53]. Given the role of tumor cell-derived 
hBD3 in promoting tumorigenesis, our findings suggest 
that high-risk HPVs induce hBD3 expression through 
regulation of cellular p53 and ΔNp63α, a novel pathway 
that facilitates progression of HPV-associated cancers.
Taken together, our data have identified a novel 
mechanism by which high-risk HPV-16, through its 
well-known virulence factor E6, utilizes the suppression 
of p53, in the presence of ΔNp63α, to induce selective 
overexpression of hBD3; an epithelial cell derived 
antimicrobial and immunoregulatory peptide that, under 
normal conditions, acts to defend mucosal surfaces from 
microbial challenges. In the context of neoplasia, hBD3 
may now be considered as a possible therapeutic target 
for the development of potential therapeutic approaches 
of head and neck cancer.
MATERIALS AND METHODS
Tissue samples, cell culture and reagents
Formalin-fixed, paraffin-embedded (FFPE) tissue 
sample protocols and waiver of informed consent as well 
as written informed consents and protocols using human 
oral keratinocytes were approved by Case Comprehensive 
Cancer Center and Case Western Reserve University 
Institutional Review Board, respectively. Primary human 
oral epithelial cells (referred as to HOECs thereafter) were 
isolated from healthy patients who underwent third-molar 
extraction at School of Dental Medicine as described [60]. 
HOECs and immortalized OKF6/TERT-2 human oral 
keratinocytes were maintained as previously described 
[2, 61]. HPV-16-positive UM-SCC-104 HNSCC cells 
([16], purchased from EMD Millipore (Billerica, MA)), 
oral cancer cell lines SasL1 [28], TR146 [2], as well as 
adenovirus type 5 (Ad5) transformed human embryonic 
kidney epithelial (HEK293) cells were maintained in 
Dulbecco’s Modified Eagle Media (DMEM) (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum 
(FBS) and Anti-Anti antibiotics (Invitrogen). Antibodies 
used in the work were: goat polyclonal anti-HPV16 E6 
(N-17) and anti-human β-defensin 3, mouse monoclonal 
anti-human p63 and -HPV-16/18 E6 (C1P5) (Santa Cruz 
Biotech., Santa Cruz, CA); mouse monoclonal anti-human 
p53 (Epitomics, Burlingame, CA); rabbit polyclonal anti-
human p53 (Abcam, Cambridge, MA), rabbit polyclonal 
anti-human acetylated-p53 (K382) (Cell Signaling, 
Danvers, MA), rabbit polyclonal anti-hBD3 (Novus, 
Littleton, CO); Alexa Fluor-conjugated donkey monoclonal 
antibodies to IgGs of various species (Invitrogen). IgGs 
of mouse and goat were purchased from Invitrogen. The 
blocking peptide to the goat polyclonal antibody to HPV-16 
E6 (N-17), HPV-16 E6 siRNA, p53 siRNA, and the control 
siRNA were purchased from Santa Cruz Biotech. Each of 
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siRNA products generally consist of pools of three to five 
target-specific 19-25 nt siRNAs designed to knockdown 
gene expression based on the manufacturer’s instructions 
(Santa Cruz Biotech). Phorbol 12-myristate-13-acetate 
(PMA), pifithrin-α, nutlin-3, and doxorubicin (DXR) were 
purchased from Sigma-Aldrich (St Louis, MO).
HPV genotyping in formalin-fixed, paraffin-
embedded (FFPE) biopsy specimens
Genomic DNA was extracted from 2-4 FFPE sections 
of HNSCC specimens using QIAamp DNA FFPE Tissue Kit 
(Qiagen Inc., Germantown, MD). High-risk HPV genotyping 
by PCR was run at 95 °C, 5 min and then 45 cycles of 95 °C 
for 30 sec., 56 °C for 30 sec, followed by 72 °C for 45 sec. In 
addition, PCR for a 133 bp β-actin gene fragment was used 
as positive control. PCR products with specific sizes were 
detected by capillary gel electrophoresis (Qiagen).
Immunofluorescence microscopy and western 
blotting
Immunofluorescence microscopy of biopsy samples 
was performed as described before [2, 3]. Fluorescent 
micrographs were taken by the EVOS fluorescence 
microscope (Life Tech). Western blotting was performed 
using the Mini-PROTEAN with pre-cast gels following 
the manufacture’s instruction (Bio-Rad, Hercules, CA). 
For hBD3 blotting, a 20% SDS-PAGE gel was used.
RNA extraction, RT-PCR, and real-time 
quantitative PCR
Total RNA was extracted using GeneElute mammalian 
total RNA isolation kit (Sigma-Aldrich) and reverse-
transcribed into the first strand cDNA using the SuperScript 
III reverse-transcriptase and hexamers (Invitrogen). Semi-
quantification of PCR products [2] and real-time quantitative 
PCR on total RNA were performed as described [62]. The 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA 
was amplified as an endogenous reference. Amplification was 
performed at 40 cycles of 94 °C for 15 s followed by 60 °C 
for 1 m and quantified. Each qPCR was run in triplicates and 
the experiment was repeated at least 3 times. For real-time 
quantitative RT-PCR of HPV-16 and -11 of HPV-16 and -11 
genes, the following primers were used (forward/reverse): 
HPV-16 E6, 5’-ATGCACCAAAAGAGAACTGCAA/5’ 
TCACACAACGGTTTGTTGTAT and HPV-11 E6, 5’-CT 
CCACGTCTGCAACATCCATAGAC/5’-TGCCTGTTGCT 
TAGAACTGCAAGGGA.
Transfection and luciferase assays
Transfection of plasmids was performed using 
Lipofectamine 2000 (Invitrogen) as described [2]. 
For promoter luciferase reporter assays, 100 ng of 
the pRL-CMV plasmid (Promega) was co-transfected 
into cells, providing an internal control to normalize 
transfection efficiency among different plasmids and 
treatments. Promoter reporter activity was determined 
using the dual luciferase kit (Promega, Madison, WI) 
following the manufacture’s protocol. Transfection and 
luciferase measurements were carried out in triplicates 
and the experiments were repeated at least three times. 
Transfection of siRNA was performed using Sigma-
Aldrich’s N-TER Nanoparticle siRNA Transfection 
System with 140 nM (CaSki cells) or 200 nM (UM-
SCC-104 cells) siRNA following the manufacture’s 
instruction.
Chromatin-immunoprecipitation (ChIP) and 
electrophoretic mobility gel shift assays (EMSA)
For ChIP assays, OKF6/TERT-2 cells cultured in 
100 mm plates were treated with doxorubicin (DXR) 
(1.25 µM) for 5 hr to activate p53. Cells without treatment 
were used as a control. ChIP assays were performed 
using the ChIP Assay Kit following the manufacture’s 
instruction (Upstate Biotechnology, Lake Placid, 
NY). The mouse monoclonal antibody to human p53 
(Epitomics) was use to precipitate the protein-DNA 
complexes. DNA was purified and subjected to qPCR 
with primers 5’-TGATTGAGCTCCACTCTTGGCTCA 
and 5’-AGGTGAGGGTGAAGTGGATGAGA. The 
abundance of p53 binding was calculated by 2^-ΔCt, 
where ΔCt was determined by subtraction of the Ct 
of DNA of p53 antibody precipitation from that of 
DNA from control IgG incubation. The ChIP assay 
was repeated two times. For EMSA, oligonucleotides 
were synthesized with biotin labeling on the 3’-end 
(Integrated DNA Tech., Coralville, IA) with the sequences: 
5’-TGACTGTCTGCCCATCTACCTGGCCCTACAT-biotin 
and the mutant probe 5’-TGACTGTCGACCCATCTACCTG
GCCCTAAATTG-biotin (mutant nucleotides are underlined). 
Recombinant p53 protein (100 ng) (Excellgen, Rockville, 
MD) was added to 100 nM annealed biotin labeled probes in 
a binding buffer and EMSA was performed as described [63]. 
The gels were then transferred to a Nylon membrane and the 
DNA/protein complexes were visualized by the LightShift 
Chemiluminescent EMSA Kit (Pierce Biotech, Rockford, IL).
Statistics
Real-time quantitative RT-PCR and relative 
luciferase activity results of treatments were compared 
with those of respective controls. The data were subjected 
to two-tailed paired Student’s t-test with two-sample 
equal variance for comparison of two groups. p≤0.05 was 
considered to be statistically significant. Data analyses 
were performed and graphs were generated using Minitab 
program (Minitab Inc.) and Excel 2010 (Microsoft, 
Seattle, WA).
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